Varda's Vision: Making Space Manufacturing Mainstream
The future of space manufacturing is closer than you think. Will Bruey, CEO of Varda Space Industries, has a bold vision: a future where space-manufactured pharmaceuticals become the norm. He predicts that within a decade, we could witness multiple spacecraft, each carrying specialized drugs, returning to Earth like shooting stars. And in 15 to 20 years, it might be more affordable to send someone to orbit for a month than to keep them on Earth.
But here's the twist: Bruey's confidence stems from his firsthand experience at SpaceX. He witnessed the evolution of reusable rockets, which seemed like a distant dream just a few years ago. Now, he believes space manufacturing is the next frontier.
Proving the Concept
Varda has already demonstrated the feasibility of its concept. In February 2024, they achieved a significant milestone by becoming the third entity to bring back a product from orbit—ritonavir crystals, an HIV medication. This success was the culmination of a lengthy regulatory process. Since then, Varda has completed several missions, each bringing back valuable pharmaceuticals.
The company's spacecraft, the W-1 capsule, is a compact, cone-shaped vessel that houses the pharmaceutical manufacturing process. It's launched on SpaceX rideshare missions, hosted by Rocket Lab's spacecraft bus, which provides essential support during orbit.
The Magic of Microgravity
So, why manufacture crystals in space? Microgravity eliminates the forces that hinder crystal formation on Earth, such as sedimentation and gravity. This allows Varda to precisely control crystallization, resulting in uniform crystals or even novel polymorphs. These improvements can lead to better drug stability, purity, and shelf life.
The process, however, is not without its challenges. Pharmaceutical manufacturing in orbit can take weeks or months. Once complete, the capsule detaches and re-enters Earth's atmosphere at astonishing speeds, protected by a NASA-developed heat shield.
A New Perspective on Space
Bruey emphasizes that Varda is not just a space company; it's an in-space industry player. Space, he argues, is simply another destination for shipping. Imagine a bioreactor with knobs for temperature, stir rate, and pressure, and Varda is adding a 'gravity knob' to the mix.
And this is the part most people miss: Varda isn't inventing new drugs but enhancing existing ones. Companies like Bristol Myers Squibb and Merck have already conducted successful crystallization experiments on the International Space Station, proving the concept's validity. Varda aims to commercialize this process by making it repeatable, reliable, and scalable for the pharmaceutical industry.
The Perfect Timing
The timing of Varda's venture is crucial. Two significant changes have made this possible. Firstly, space launches have become more accessible and predictable, allowing companies to book slots years in advance. Secondly, the availability of off-the-shelf satellite buses, like Rocket Lab's Photon, has been a game-changer.
The Seven Domino Theory
Bruey presents an intriguing concept to members of Congress: the 'seven domino theory.' The first domino, reusable rockets, has already fallen. The second is manufacturing drugs in orbit and returning them, which Varda has accomplished. The third domino is the pivotal one: getting a space-manufactured drug into clinical trials, leading to perpetual launches.
Varda's business model differs from traditional satellite companies. Satellite companies launch hardware and are done; Varda's demand for launches is theoretically unlimited and grows with success. This predictable, scalable demand can drive down launch costs, benefiting the entire space industry.
The fourth domino sets off a virtuous cycle: as Varda scales, costs drop, making more drugs economically viable. This, in turn, leads to more launches and further cost reductions.
The Road Ahead
While Varda's commercial viability is yet to be proven, the potential impact is immense. Lower launch costs could open up space for various industries, from semiconductors to exotic materials. Bruey envisions a future where it's cheaper to send an employee to orbit for a month than to automate their job on Earth.
However, Varda's journey hasn't been without challenges. Their first mission faced a six-month delay due to regulatory hurdles, highlighting the complexities of commercial space operations.
The Near-Death Experience
Varda's W-1 capsule, launched in June 2023, successfully manufactured Form III ritonavir crystals in orbit. But it remained stranded for months due to landing approval issues. The Utah Test and Training Range, a military facility, prioritized military missions over Varda's landing, causing delays and regulatory complications.
The company persevered, eventually landing the W-1 capsule in February 2024, becoming the first commercial spacecraft to land on a military test range and under the FAA's Part 450 licensing framework. This achievement secured Varda landing sites in the U.S. and Australia and a unique FAA operator license.
Hypersonic Testing: A Secondary Business
Varda's capsules re-enter the atmosphere at hypersonic speeds, creating a unique testing opportunity. The extreme conditions during re-entry cannot be replicated on Earth. Varda offers valuable hypersonic testing services to defense agencies, embedding sensors and testing materials in real flight conditions.
Investor Appeal
Investors are enthusiastic about Varda's potential. The company has raised substantial funds, with a focus on building its pharmaceutical lab and hiring experts. Varda aims to tackle more complex molecules and biologics, targeting a substantial market.
While there's a long road ahead, Bruey believes the future is closer than we think. But here's where it gets controversial: is space manufacturing the next big leap for the pharmaceutical industry, or are there unforeseen challenges that could hinder its widespread adoption? Share your thoughts in the comments below!
